Global Trends Review: The Rapid Evolution of the Diabetic Kidney Disease Market

The diabetic kidney disease market is on track for significant expansion as awareness and treatment options improve. Driven by medical advancements and evolving healthcare approaches, this sector is expected to experience notable growth over the coming years. Let's explore the market size projections, key players, driving trends, and segmentation to understand the future landscape better.

Projected Market Size and Growth Trajectory of the Diabetic Kidney Disease Market
The diabetic kidney disease market is anticipated to reach a value of $3.76 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.1%. This positive outlook is fueled by breakthroughs in renal protective medications, increased efforts for early diagnosis, a rising burden of chronic kidney disease, expansion in specialized nephrology services, and a shift towards personalized treatment plans. Key trends expected to shape the market in the forecast period include wider adoption of early kidney screening techniques, increased utilization of renoprotective drug therapies, growth in combination treatment methods, a stronger emphasis on delaying disease progression, and more integrated, multidisciplinary care models.

Download a free sample of the diabetic kidney disease market report:
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Influencing the Diabetic Kidney Disease Market
Several prominent companies play a crucial role in the diabetic kidney disease market, including AstraZeneca plc, Pfizer Inc., Novartis AG, Bayer AG, Sanofi SA, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Fresenius SE & Co. KGaA, F. Hoffmann-La Roche AG, Abbott Laboratories, Reata Pharmaceuticals Inc., Merck & Co., Mitsubishi Tanabe Pharma Corporation, Johnson & Johnson Pvt. Ltd., Eli Lilly and Company, GlaxoSmithKline plc, AbbVie Inc., Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co. Ltd., and Daiichi Sankyo Company Limited.

In a strategic move in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology firm, acquired Cincor Pharma Inc. for an undisclosed sum. This acquisition strengthens AstraZeneca's cardiorenal pipeline by incorporating CinCor's investigational drug, baxdrostat (CIN-107), which is an aldosterone synthase inhibitor (ASI) aimed at reducing blood pressure in patients with treatment-resistant hypertension. Cincor Pharma Inc., headquartered in the US, specializes in developing therapies targeting kidney disease management.

View the full diabetic kidney disease market report:
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Positively Impacting Growth in the Diabetic Kidney Disease Market
Major players in the diabetic kidney disease field are increasingly leveraging advanced technologies like artificial intelligence (AI) to improve early risk prediction, enable personalized treatment, and optimize long-term patient outcomes. AI-enabled prognostic platforms combine blood biomarker data with machine learning algorithms to forecast the risk of kidney function decline, facilitating risk scoring, patient classification, and proactive clinical decision-making.

For example, in June 2023, UK-based diagnostics company Renalytix plc received FDA De Novo marketing clearance for KidneyIntelX.dkd, an AI-driven prognostic tool designed to assess the likelihood of significant kidney function deterioration in adults with type 2 diabetes and early-stage chronic kidney disease. This platform integrates biomarker data with machine learning, cloud-based workflows, and risk stratification reports to improve clinical guidance, support targeted monitoring, and enhance proactive care plans.

Segment-Wise Market Share and Forecast in the Global Diabetic Kidney Disease Market
This report segments the diabetic kidney disease market based on the following criteria:

By Type:
- Type 1 Diabetes
- Type 2 Diabetes

By Treatment:
- Angiotensin Receptor Blockers (ARBs)
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Antioxidant Inflammation Modulators
- Calcium Channel Blockers
- Other Treatments

By End User:
- Hospitals
- Homecare Settings
- Specialty Centers
- Other End Users

Further subcategories include:

For Type 1 Diabetes:
- Autoimmune-Related Diabetic Kidney Disease
- Early-Onset Diabetic Kidney Disease

For Type 2 Diabetes:
- Obesity-Related Diabetic Kidney Disease
- Late-Onset Diabetic Kidney Disease

This segmentation allows for a comprehensive understanding of market dynamics and targeted opportunities within each category.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.